机构:[1]Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown,USA[2]Department of Biology, School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine,Shanghai, China[3]Department of Liver Diseases, Guangdong Hospital of Traditional Chinese Medicine in Zhuhai,Zhuhai, China大德路总院珠海院区外科大德路总院外一科广东省中医院[4]Department of Neuroscience, Karolinska Institute, Stockholm, Sweden[5]Division of Geriatrics andNutritional Science, Washington University School of Medicine, St.Louis, USA
Lipin-1 is a phosphatidate phosphohydrolase (PAP) required for the generation of diacylglycerol during glycerolipid synthesis, and exhibits dual functions in the regulation of lipid metabolism. Lipin-1 has been implicated in the pathogenesis of alcoholic liver disease (ALD). In the present study, we assessed lipin-1 function in myeloid cells in ALD using a myeloid cell-specific lipin-1 knockout (mLipin-1KO) mouse model. Utilizing the Gao-binge ethanol feeding protocol, matched mLipin-1KO mice and littermate loxP control (WT) mice were pair-fed with either an ethanol-containing diet or an ethanolfree diet (control). Surprisingly, deletion of lipin-1 in myeloid cells dramatically attenuated liver inflammatory responses and ameliorated liver injury that would normally occur following the ethanol feeding protocol, but slightly exacerbated the ethanol-induced steatosis in mice. Mechanistically, myeloid cell-specific lipin-1 deficiency concomitantly increased the fat-derived adiponectin and ileumderived fibroblast growth factor (FGF) 15. In concordance with concerted elevation of circulating adiponectin and FGF15, myeloid cell-specific lipin-1 deficiency diminished hepatic nuclear factor kappa B (NF-kappa B) activity, limited liver inflammatory responses, normalized serum levels of bile acids, and protected mice from liver damage after ethanol challenge. Our novel data demonstrate that myeloid cell-specific deletion of lipin-1 ameliorated inflammation and alcoholic hepatitis in mice via activation of endocrine adiponectin-FGF15 signaling.
基金:
National Institute on Alcoholism and Alcohol Abuse (AA013623
and AA015951 to M You) and National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK078187
to BN Finck). We thank Dr. Xiaomei Liang (University of South Florida) for her excellent technical assistance.
We are grateful to Dr. Junchang Zhang (Guangdong Hospital of Traditional Chinese Medicine in Zhuhai) for
insightful discussions related to the alcoholic- and nonalcoholic liver diseases. Dr. Hong Shen is supported by
Natural Science Foundation of China, grant # 81273967.